ConceptioArchiveClinicalTrials.gov
ClinicalTrials.govpublic full text

Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma

University of California, San Diego · 2025
ClinicalTrials.gov · Datasets · License: Public Domain · 2025
Open Source ↗
basalcellcarcinoma
basal cell carcinoma, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 841725
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.